Scientists have finally cracked one of the biggest mysteries in the senses: how smell is organized. By mapping millions of neurons in mice, researchers discovered that smell receptors in the nose aren’t random at all—they’re arranged in neat, overlapping stripes based on receptor type, forming a hidden structure scientists never knew existed. Even more striking, this layout mirrors how smell information is mapped in the brain, revealing a coordinated system from nose to neural circuits.

The body’s “killer” T cells don’t just attack—they strike with astonishing precision, forming a tiny, highly organized contact zone that lets them destroy dangerous cells without harming their neighbors. Now, scientists have captured this process in unprecedented detail, revealing a hidden world of molecular choreography.

A troubling new study from MIT reveals that a common environmental contaminant, NDMA—found in polluted water, certain medications, and even processed foods—may pose a far greater cancer risk to children than adults. In experiments with mice, young animals exposed to the chemical developed significantly more DNA damage and cancer, despite experiencing the same initial exposure as adults. The key difference lies in how rapidly children’s cells divide, which turns early DNA damage into dangerous mutations much more easily.

A daily vitamin D supplement may quietly supercharge chemotherapy. In a small study, women who took low doses alongside treatment were far more likely to see their cancer vanish than those who didn’t. Since vitamin D also supports immune function—and many patients are deficient—it could be playing a bigger role than expected. Scientists say this affordable approach deserves much deeper investigation.

A new virus-fighting plastic film could transform everyday surfaces into invisible defenders against disease. Instead of relying on chemicals, this flexible material is covered in microscopic pillars that physically stretch viruses until they burst, rendering them harmless. In lab tests, it destroyed or disabled about 94% of virus particles within an hour, showing impressive effectiveness.

A newly discovered virus hiding inside a common gut bacterium could help explain one of medicine’s long-standing mysteries: why a microbe found in both healthy people and cancer patients is linked to colorectal cancer. The research suggests that the interaction between bacteria and the viruses they carry may be key to understanding disease risk. It may even lead to future screening tests that detect cancer risk earlier.

A key protein, HOXD13, helps melanoma tumors grow and evade the immune system by boosting blood supply and blocking cancer-fighting T cells. Disabling it shrinks tumors and reopens the door for the immune system—offering a new path for treatment.

Cancer cells are known for their “glutamine addiction,” but many can escape this weakness by switching to alternative fuels. Researchers found that vitamin B7 acts like a metabolic “license,” enabling this escape route through a key enzyme. Without biotin, cancer cells lose that flexibility and stop growing. Mutations in a cancer-linked gene can make this vulnerability even stronger, offering a promising new target for therapy.

A surprising new study suggests that eating a very healthy diet—packed with fruits, vegetables, and whole grains—might be linked to a higher risk of lung cancer in younger non-smokers. Researchers found that patients under 50 diagnosed with lung cancer often had better-than-average diets, raising the possibility that pesticide exposure from conventionally grown produce could be a hidden culprit.

Scientists have taken a major step toward stopping Epstein-Barr virus (EBV), an extremely common infection linked to cancer and chronic disease. By using mice engineered with human antibody genes, researchers created powerful human-like antibodies that block the virus from attaching to and entering immune cells. One of these antibodies completely prevented infection in lab models with human immune systems, marking a breakthrough after years of difficulty tackling EBV’s ability to invade nearly all B cells.

A new study reveals that popular diabetes and weight-loss drugs like Ozempic and Wegovy may not work as effectively for about 10% of people due to specific genetic variants. These individuals appear to have a puzzling condition called “GLP-1 resistance,” where their bodies produce higher levels of the hormone targeted by these drugs—but don’t respond to it properly.

Researchers are launching a new project to crack the mystery of aggressive breast cancer, where predicting disease progression remains a major hurdle. By studying how tumors interact with and suppress the immune system, scientists aim to identify new biomarkers that reveal how the cancer evolves. Using real patient samples, the team hopes to turn earlier discoveries into practical clinical tools. The goal: more precise, personalized treatments that can outsmart even the most dangerous tumors.

A new nanodisc-based platform lets scientists study viral proteins in a form that closely mimics real viruses, revealing how antibodies truly recognize them. This approach uncovered hidden interactions in viruses like HIV and Ebola that traditional methods missed. By recreating the virus’s membrane environment, researchers can better understand how immune defenses work. The technique could speed up the development of more effective vaccines.

Researchers have uncovered why a rare blood clotting disorder can occur after certain COVID-19 vaccines or adenovirus infections. The immune system can mistakenly target a normal blood protein (PF4) after confusing it with a viral protein. This triggers clotting in extremely rare cases. The breakthrough means vaccines can now be redesigned to avoid this reaction while staying effective.

A common eye-health nutrient, zeaxanthin, may also help the body fight cancer more effectively. Scientists discovered it strengthens T cells and enhances the impact of immunotherapy treatments. Found in everyday vegetables and supplements, it’s safe, accessible, and shows strong potential as a cancer therapy booster. Human trials are the next step.

Cancer drugs known as BET inhibitors once looked like a breakthrough, but in real patients they’ve often fallen short. New research reveals a key reason why: two closely related proteins, BRD2 and BRD4, don’t actually do the same job. Instead, BRD2 acts like a “stage manager,” preparing genes for activation, while BRD4 triggers the final step that turns them on. By blocking both at once, current drugs may be disrupting the process in unpredictable ways.

Vitamin D levels in midlife may play a bigger role in long-term brain health than previously thought. In a study following nearly 800 people over 16 years, those with higher vitamin D levels in their 30s and 40s had lower levels of tau protein later on, a key marker linked to dementia.

Scientists have identified a little-known receptor, GPR133, as a powerful regulator of bone strength. By activating it with a newly discovered compound called AP503, they were able to boost bone density in mice and counteract osteoporosis-like damage. The finding opens the door to a new kind of treatment that could not only prevent bone loss but also rebuild weakened bones, offering fresh hope for millions affected by osteoporosis, especially aging populations.

Scientists have identified a potential new weapon against hepatitis E, a virus with no approved treatment and tens of thousands of deaths each year. The drug bemnifosbuvir, currently in trials for hepatitis C, was found to block the virus from replicating by disrupting its genetic machinery. Tests in cells and animals showed strong effectiveness without harming healthy tissue. If ongoing trials succeed, the drug could soon be repurposed for hepatitis E.

Scientists in Canada have uncovered a surprising weakness in glioblastoma, one of the deadliest brain cancers. They found that certain brain cells—once believed to only support healthy nerves—can actually help tumors grow by sending signals that strengthen cancer cells. When researchers blocked this communication, tumor growth slowed dramatically in lab models.

Colorectal cancer may carry a unique microbial “fingerprint,” setting it apart from other cancers and opening a new frontier in diagnosis and treatment. By analyzing DNA from over 9,000 patients, researchers discovered that only colorectal tumors consistently host distinct microbial communities—challenging the long-held belief that all cancers have their own microbial signatures.

A large U.S. study reveals that more than a quarter of people with hard-to-treat high blood pressure may have an overlooked hormone problem. Elevated cortisol—often linked to stress—was found in 27% of these patients, far higher than expected. This hidden condition could explain why standard medications fail. The discovery could lead to new testing and treatments that finally help bring blood pressure under control.

A powerful cholesterol-lowering drug may be changing the rules of heart disease prevention. Researchers found that evolocumab, typically used for people who already have cardiovascular disease, can significantly cut the risk of first-time heart attacks and strokes in high-risk patients with diabetes—even before any artery-clogging plaque is detected.

A major new U.S. cholesterol guideline is shifting the focus toward earlier, more personalized prevention of heart disease. It urges people to start screening sooner—sometimes even in childhood—and highlights the importance of tracking not just LDL (“bad”) cholesterol but also genetic risk factors like lipoprotein(a). A new, more advanced risk calculator now uses broader health data to better predict heart attack and stroke risk over decades.

Scientists have uncovered a hidden reason why cancer treatments don’t work equally well for everyone. Certain drugs can become trapped inside lysosomes within tumor cells, forming slow-release reservoirs that create uneven drug distribution. This means some cancer cells are heavily exposed while others are barely affected. Understanding this process could help doctors better tailor treatments and improve outcomes.

Scientists have discovered that losing a key protein in small cell lung cancer triggers inflammation that actually helps tumors grow and spread. Even more surprising, it pushes cancer cells into a more aggressive, neuron-like state linked to relapse.

Researchers have identified microRNA-93 as a key genetic driver of fatty liver disease and discovered that vitamin B3 can effectively shut it down. This finding suggests a safe, widely available vitamin could become a powerful new treatment.

Postmenopausal women may have a powerful new edge in the battle against weight gain. A Mayo Clinic study found that those using menopausal hormone therapy while taking the obesity drug tirzepatide lost about 35% more weight than those on the drug alone. The findings hint at a surprising synergy between hormones and cutting-edge weight-loss medications, potentially opening the door to more effective, personalized treatments for millions of women facing increased cardiometabolic risks after menopause.

A new blood test could change the outlook for one of the deadliest cancers—pancreatic cancer—by catching it much earlier than ever before. Researchers identified two previously unknown proteins in the blood that, when combined with existing markers, dramatically improved detection accuracy. The four-marker test was able to spot pancreatic cancer in over 90% of cases and performed especially well even in early stages, when treatment has the best chance of success.

A new pill, enlicitide, reduced LDL (“bad”) cholesterol by about 60% in a large clinical trial, matching the power of injectable therapies. Because it’s taken orally, it could overcome one of the biggest barriers keeping patients from using current treatments. Researchers say many people still don’t reach safe cholesterol levels—even on statins—highlighting the need for better options.

Researchers have discovered that cancer spread isn’t random—it follows a kind of biological “program.” By studying colon tumor cells, they identified gene patterns that signal whether a cancer is likely to metastasize. Their AI model, MangroveGS, can predict this risk with about 80% accuracy and even works across multiple cancer types. This could transform how doctors decide who needs aggressive treatment and who doesn’t.

A shingles vaccine might double as a powerful heart protector. In people already at high risk, it cut major cardiac events by 46% and deaths by an impressive 66% within a year. Scientists think preventing shingles may also stop clot-related complications that can lead to heart attacks and strokes. The effect is so strong, it rivals the benefits of quitting smoking.

Scientists have found a way to make one of the most aggressive brain tumors vulnerable to the immune system. A single injection of a modified virus can invade glioblastoma, kill cancer cells, and summon immune fighters deep into the tumor. These immune cells persist and attack, which was linked to longer survival in patients.

A common oral bacterium tied to gum disease may help spark and fuel breast cancer, according to new research. Scientists discovered it can travel through the bloodstream to breast tissue, where it causes DNA damage and speeds tumor growth and spread. It also appears to make cancer cells more aggressive and resistant to therapy. The effect is even stronger in people with BRCA1 mutations, raising new questions about the role of oral health in cancer risk.

Scientists have mapped the genetics of cancer in cats for the first time at scale, uncovering major overlaps with human cancers. Key mutations—like those linked to breast cancer—appear in both species, and some human cancer drugs may also work in cats. Because pets share our environments, these similarities could reveal shared causes of cancer. The research could lead to new treatments that benefit both animals and humans.

mRNA vaccines saved millions of lives during COVID-19 but have limitations like waning immunity and complex production. Scientists are now testing a new platform called DoriVac, which uses folded DNA nanostructures to better control how the immune system responds. In early studies, it produced strong antibody and T cell responses in both mice and human models. Researchers say it could lead to more stable, easier-to-manufacture vaccines for diseases like COVID-19, HIV, and Ebola.